Human neutrophil-derived extracellular vesicles induce renal endothelial inflammation in critical illness: an ex vivo investigation.
Summary
Ex vivo NEVs from healthy blood (LPS-stimulated) and from COVID-19 ARDS patients were internalized by monocytes, activating p38 MAPK and boosting TNF release, which in turn drove inflammatory activation of renal glomerular endothelial cells. Findings support a monocyte-dependent mechanism by which circulating NEVs contribute to AKI in ARDS and highlight p38/TNF pathways as potential targets.
Key Findings
- NEVs were internalized by monocytes and activated them via p38 MAPK, increasing TNF release.
- NEV exposure led to inflammatory activation of renal glomerular endothelial cells in co-culture.
- Monocyte-dependent mechanisms mediated endothelial inflammation, implicating p38/TNF pathways as targets.
Clinical Implications
Suggests exploring therapeutics that modulate NEV signaling, p38 MAPK inhibition, or TNF pathways to prevent or mitigate AKI in ARDS. Biomarker development around NEVs could aid risk stratification for renal complications.
Why It Matters
Provides mechanistic evidence linking circulating NEVs to renal endothelial inflammation in ARDS, identifying actionable signaling pathways (p38 MAPK/TNF). Such organ cross-talk insights can guide targeted interventions for AKI in critical illness.
Limitations
- Ex vivo design with short incubation (4 h) limits direct in vivo generalizability.
- Sample size and patient heterogeneity are not fully detailed in the abstract; clinical outcomes were not assessed.
Future Directions
Validate NEV-mediated pathways in vivo, quantify NEV phenotypes in larger ARDS cohorts, and test p38/TNF-targeted interventions to prevent AKI.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - Observational comparative study with ex vivo mechanistic experiments using patient vs control samples
- Study Design
- OTHER